Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) announced that its subsidiary, Shang Pharma Kangli (Changzhou) Pharmaceutical Co., Ltd., recently received a notification of approval for the market application of the Isavuconazole Sulfate active pharmaceutical ingredient from the National Medical Products Administration.

The approval, with certificate number 2025YS01127, grants permission for the commercial production of the ingredient. This signifies that the API complies with the relevant regulations for domestic pharmaceutical registration and is cleared for sale in the Chinese market.

Furthermore, the approval of the Isavuconazole Sulfate API provides valuable experience for the company's future initiatives in API registration and development. The aforementioned matter is not expected to have a significant impact on the company's current operating performance.